We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

133 hedge funds and large institutions have $365M invested in Rigel Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 50 increasing their positions, 32 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more call options, than puts

Call options by funds: $1.73M | Put options by funds: $881K

56% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 32

0.11% more ownership

Funds ownership: 9.41% → 9.52% (+0.11%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

6% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 16

1% less funds holding

Funds holding: 135 → 133 (-2)

27% less capital invested

Capital invested by funds: $503M → $365M (-$138M)

Holders
133
Holders Change
-2
Holders Change %
-1.48%
% of All Funds
2.96%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
50
Reduced
32
Closed
16
Calls
$1.73M
Puts
$881K
Net Calls
+$848K
Net Calls Change
+$1.49M

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$5.69M
2
Citadel Advisors
Citadel Advisors
Florida
+$3.91M
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$3.29M
4
TA
Tamarack Advisers
California
+$2.68M
5
UBS Group
UBS Group
Switzerland
+$1.95M

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$7.86M
2
BC
Boxer Capital
California
-$7.45M
3
Millennium Management
Millennium Management
New York
-$2.13M
4
BRF
B. Riley Financial
California
-$1.52M
5
MWNA
Marshall Wace North America
New York
-$1.17M
Name Holding Trade Value Shares
Change 		Change in
Stake
AllianceBernstein
26
AllianceBernstein
Tennessee
$3.09M – – –
State of New Jersey Common Pension Fund D
27
State of New Jersey Common Pension Fund D
New Jersey
$1.96M – – –
Citigroup
28
Citigroup
New York
$1.8M +$277K +9,811 +14%
Two Sigma Investments
29
Two Sigma Investments
New York
$1.71M +$373K +13,210 +22%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$1.65M +$68.9K +2,443 +4%
Fuller & Thaler Asset Management
31
Fuller & Thaler Asset Management
California
$1.62M -$1.81K -64 -0.1%
UBS Group
32
UBS Group
Switzerland
$1.6M +$1.95M +69,051 +12,331%
Bank of America
33
Bank of America
North Carolina
$1.35M +$1.54M +54,393 +1,294%
Assenagon Asset Management
34
Assenagon Asset Management
Luxembourg
$1.34M +$1.65M +58,297 New
WMSA
35
Weiss Multi-Strategy Advisers
New York
$1.17M +$42.3K +1,500 +3%
Allianz Asset Management
36
Allianz Asset Management
Germany
$1.11M -$48.5K -1,717 -3%
California Public Employees Retirement System
37
California Public Employees Retirement System
California
$1.1M -$79.3K -2,809 -6%
USAA
38
United Services Automobile Association
Texas
$898K – – –
Charles Schwab
39
Charles Schwab
California
$845K – – –
Marshall Wace
40
Marshall Wace
United Kingdom
$773K +$572K +20,277 +152%
PVI
41
Pura Vida Investments
New York
$764K +$83.4K +2,957 +10%
TA
42
Teachers Advisors
New York
$737K – – –
TCIM
43
TIAA CREF Investment Management
New York
$709K -$6.58K -233 -0.8%
Swiss National Bank
44
Swiss National Bank
Switzerland
$643K +$23.7K +840 +3%
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$605K +$24.7K +874 +3%
TI
46
Telemetry Investments
New York
$598K +$392K +13,900 +115%
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$502K +$202K +7,149 +49%
CS
48
Credit Suisse
Switzerland
$501K +$164K +5,816 +36%
Susquehanna International Group
49
Susquehanna International Group
Pennsylvania
$477K +$585K +20,741 New
NSEDCP
50
NJ State Employees Deferred Compensation Plan
New Jersey
$460K +$56.4K +2,000 +11%
1
2
3 4 5

RIGL Hedge Fund Activity: Q4 2018 in Review

133 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2018, worth a combined $365M — down 27% from $503M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of RIGL and 15 opened new positions — a net loss of 1 holder — while 32 trimmed existing stakes and 50 added.

The largest buyer was Goldman Sachs, adding an estimated $5.69M. The largest seller was Vanguard Group, cutting an estimated $7.86M.

  • 133 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2018, down from 135 in Q3 2018.
  • Funds reported $365M of Rigel Pharmaceuticals stock for Q4 2018, down 27% quarter-over-quarter.
  • 15 funds opened new Rigel Pharmaceuticals positions in Q4 2018 and 16 closed out, a net change of -1 holder.
  • The largest Rigel Pharmaceuticals buyer in Q4 2018 was Goldman Sachs, an estimated $5.69M added.
  • The largest Rigel Pharmaceuticals seller in Q4 2018 was Vanguard Group, an estimated $7.86M sold.

Based on aggregated 13F filings for Q4 2018.